These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22972180)

  • 1. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
    Harashima SI; Tanaka D; Yamane S; Ogura M; Fujita Y; Murata Y; Seike M; Koizumi T; Aono M; Wang Y; Inagaki N
    Horm Metab Res; 2013 Mar; 45(3):231-8. PubMed ID: 22972180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
    Harashima SI; Ogura M; Tanaka D; Fukushima T; Wang Y; Koizumi T; Aono M; Murata Y; Seike M; Inagaki N
    Int J Clin Pract; 2012 May; 66(5):465-76. PubMed ID: 22512606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
    Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
    Hong ES; Khang AR; Yoon JW; Kang SM; Choi SH; Park KS; Jang HC; Shin H; Walford GA; Lim S
    Diabetes Obes Metab; 2012 Sep; 14(9):795-802. PubMed ID: 22443183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
    Takahara M; Shiraiwa T; Katakami N; Matsuoka TA; Shimomura I
    Diabetes Technol Ther; 2014 Oct; 16(10):633-9. PubMed ID: 24949654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.
    Philis-Tsimikas A; Del Prato S; Satman I; Bhargava A; Dharmalingam M; Skjøth TV; Rasmussen S; Garber AJ
    Diabetes Obes Metab; 2013 Aug; 15(8):760-6. PubMed ID: 23577643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
    Hollander P; Raslova K; Skjøth TV; Råstam J; Liutkus JF
    Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.